What is Teva Pharmaceutical Industries FCF Yield %?
Teva Pharmaceutical IndustriesBSP:T1EV34 11 FCF Yield % is 2.88 as of Jul. 05, 2026, which is 35% below its 10-year median of 4.43. GuruFocus rates BSP:T1EV34 with a GF Score™ of 11/100 and a GF Value™ of R$52.51 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,004 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks better than 64.94% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Teva Pharmaceutical Industries FCF Yield % Related Terms
Teva Pharmaceutical Industries FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:T1EV34 vs ZTS, UTHR, VTRS: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries (BSP:T1EV34) has a FCF Yield % of 2.88 as of Jul. 05, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Teva Pharmaceutical Industries and its competitors. This is 35% below median its historical median of 4.43. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #352 out of 1004 companies in the Drug Manufacturers industry, placing it in the top 35.1%.
Is Teva Pharmaceutical Industries' FCF Yield % too high?
Teva Pharmaceutical Industries' current FCF Yield % of 2.88 is 35% below median its 10-year median of 4.43. The Drug Manufacturers industry median FCF Yield % is 0.67. Teva Pharmaceutical Industries' value of 2.88 is 333.1% above this industry median. Based on the distribution chart, Teva Pharmaceutical Industries ranks #352 out of 1004 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Teva Pharmaceutical Industries has a GF Score™ of 11/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #352 out of 1004 companies for FCF Yield %. This puts Teva Pharmaceutical Industries in the upper half of its industry. The industry median FCF Yield % is 0.67. Teva Pharmaceutical Industries' value of 2.88 is 333.1% above this benchmark. While the company's 10-year median is 4.43 vs. the industry median of 0.67, Teva Pharmaceutical Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,004 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current FCF Yield % of 2.88 is 333.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Teva Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current FCF Yield % is 2.88, which is 35% below median its own 10-year median of 4.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (BSP:T1EV34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$52.51, compared to a current price of R$89.28 — trading 70% above its estimated fair value. The current FCF Yield % is 2.88, which is 35% below median its 10-year median of 4.43 and 333.1% above the Drug Manufacturers industry median of 0.67. Teva Pharmaceutical Industries' overall GF Score™ is 11/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Teva Pharmaceutical Industries (BSP:T1EV34), the current FCF Yield % is 2.88 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued.
The current stock price of R$89.28 is trading 70% above its estimated GF Value™ of R$52.51.
GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.
Key valuation signals for BSP:T1EV34:
FCF Yield %: 2.88 (35% below median its 10-year median of 4.43)
GF Value™: R$52.51 vs. price of R$89.28 (70% above fair value)
Industry Position: 333.1% above the Drug Manufacturers median (#352 of 1004)
No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teva Pharmaceutical Industries Business Description
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
11GF Score
Get the complete analysis for BSP:T1EV34
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:T1EV34 has been successfully added to your 
